Membership: Join my YouTube channel membership and unlock exclusive perks! As a member, you'll get early access to videos to stay ahead with the latest content before anyone else. Investor tier members get access to my spreadsheets, and VIP discord members get access to our private discord community
1 extracted signal · 1 resolved · 0 still active
Parkev Tatevosian, CFA24 Sept 2025, 04:48 UTC
AI-generated source summary
The video discusses HIMS stock, revisiting a previous buy recommendation from August 5th, 2025. The stock has risen almost 30% in the past month, warranting a reevaluation. The analysis focuses on the company's revenue growth, which has increased from $100 million to $2 billion between 2020 and 2025, resulting in a 79% compound annual growth rate. Even without the weight loss treatments, revenue and customer growth are reportedly strong. The company's operating profit margin is 6.5% in the trailing 12-month period, up from -39% in 2021. The largest expense for HIMS is sales and marketing, which benefits from economies of scale as the company grows. While there are claims that HIMS is selling copycat versions of the weight loss treatments, the management reports growing.
AI-generated summary based on the source content.
Evidence and evaluation progress
- Original source published
The analyst published the original source item.
- First prediction resolved
The first evaluable outcome in this case reached a terminal result.
- Case evaluation completed
All evaluable predictions in this case reached terminal outcomes.
- Source recorded by Tahlil Plus
The public source was preserved as the evidence record for this case.
- Market predictions extracted
1 eligible signal linked to this case.
- Outcome tracking started
Tahlil Plus began monitoring the extracted predictions.
Signals in this source
More Prediction Case Files from Parkev Tatevosian, CFA
Coca-Cola Stock: Buy, Hold, or Sell? | KO Stock Analysis
SoFi Stock Analysis: Buy the Dip?
Should You Buy Micron Stock Instead of Nvidia Stock? | MU Stock vs. NVDA Stock
Should You Buy the Dip in Meta Stock? | META Stock Analysis and Live Earnings Review
Should Passive Income Investors Buy Colgate Palmolive Stock?
Procter & Gamble Stock: Buy, Hold, or Sell? | PG Stock Analysis
Parkev Tatevosian, CFA
Tahlil Plus independently records and evaluates public market predictions. Extraction may be AI-assisted and results follow the Tahlil Plus methodology. This information is not financial advice.